Volume 24, Number 3—March 2018
Research
Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000–2015
Miranda G. Loutet
, Jennifer A. Davidson, Tim Brown, Martin Dedicoat, H. Lucy Thomas, and Maeve K. Lalor
, Jennifer A. Davidson, Tim Brown, Martin Dedicoat, H. Lucy Thomas, and Maeve K. Lalor
Table 2
Description of acquired drug resistance profiles used to categorize resistance to anti-TB drugs*
| Acquired drug resistance profile | Description of drug-resistance profile |
|---|---|
| TB patients who did not have MDR TB before or after acquiring resistance | Initially sensitive to isoniazid, rifampin, or both and may have acquired resistance to either isoniazid or rifampin but not both or may have acquired resistance to other anti-TB drug(s). |
| TB patients who acquired resistance that resulted in MDR TB | Initially sensitive to isoniazid, rifampin, or both and acquired resistance to isoniazid, rifampin, or both to have MDR TB. |
| Patients with initial MDR TB and acquired resistance to additional drugs | Initially resistant to at least isoniazid and rifampin and on subsequent culture acquired resistance to other anti-TB drug(s). |
*MDR, multidrug-resistant; TB, tuberculosis.
Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.